Get in the Groove and Tune Up Your Pitch at Two Groundbreaking RESI Events from Life Science Nation  

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) is proud to embark on our inaugural RESI London, taking place December 4-6, 2024, and the milestone 50th RESI JPM, scheduled for January 14-16, and 21, 2025, offer unparalleled opportunities for companies to jumpstart their fundraising efforts and shape their future in the industry. RESI London: A European Springboard, imagine stepping into the heart of the UK’s vibrant life science ecosystem at RESI London, co-located with Genesis 2024. This event isn’t just a conference; it’s a launchpad for companies looking to make their mark in Europe. Here, you’ll have the chance to refine your pitch for a discerning European audience, engage with elite investors and licensing partners, and showcase your innovation in the Innovator’s Pitch Challenge (IPC). The hybrid format, combining an in-person day with two days of virtual partnering, ensures you can maximize your reach and flexibility. RESI JPM: Where 2025 Global Partnering Roadshows Take Flight. As the calendar turns, RESI JPM in San Francisco beckons, offering a global stage amidst the energy of JPM Healthcare Conference week. This flagship event is your ticket to connecting with over 600 investors spanning the “4 Ds” – Drugs, Devices, Diagnostics, and Digital Health, as well as R&D Tools and Services. Picture yourself pitching to a panel of industry luminaries, forging connections that could define your company’s future, and kicking off the year with momentum that could carry you through 2025 and beyond.

The Art of Refinement

Remember the old joke about getting to Carnegie Hall? “Practice, practice, practice.” The same principle applies here. By participating in both RESI London and RESI JPM, you’re not just attending events; you’re embarking on a journey of refinement. Each interaction, each pitch, each conversation is an opportunity to hone your message, gain invaluable feedback, and build a global network that could be the key to your success.

LSN’s Global Partnering Ecosystem Is Your Secret Weapon

Behind these events lies LSN’s global partnering ecosystem. This isn’t just a network; it’s a sophisticated matchmaking system that spans the “4 Ds” and beyond, including R&D Tools, Services, and AI. With curated data profiles ensuring precise matches and a series of worldwide partnering events, LSN offers you a comprehensive toolkit for navigating the complex landscape of life science innovation and investment.

A Strategic One-Two Punch

Attending both RESI London and RESI JPM isn’t just about being present; it’s about strategic positioning. Use RESI London as your European warm-up, refining your approach for a continental audience. Then, take those lessons learned and amplify your impact at RESI JPM, where you’ll be primed to make a lasting impression on the global stage. This continuous engagement across two major markets isn’t just networking; it’s momentum-building at its finest. The time to act is now. By securing your place at both RESI London and RESI JPM, you’re not just registering for events; you’re investing in your company’s future. With LSN’s tailored support guiding you every step of the way, you’ll be equipped to navigate the challenges of the life science landscape and transform your innovative ideas into reality. Don’t let this opportunity pass you by – your next big breakthrough could be just one connection away.

Register for  RESI London Register for RESI JPM

RESI-London-2024-1100px

RESI-JPM-2025-1100PX

Upcoming Investor Fireside Chat Webinar: Exploring Early-Stage Investment Opportunities with Insights from RESI Conferences 

By Momo Yamamoto, Senior Investor Research Analyst, LSN

For startups and innovators in the life sciences sector, early-stage funding is often one of the most critical yet challenging aspects of launching groundbreaking projects. As investors increasingly recognize the potential for high impact returns in biotechnology and life sciences, they are actively seeking investment opportunities that align with their goals and expertise. To shed light on the latest trends and strategies for securing early-stage funding, we’re thrilled to announce an upcoming webinar, co-moderated by Labiotech. For over a decade, Labiotech.eu has grown to be the most visited biotech website in Europe and a trusted source of information, dedicated to providing the biotech community with current and relevant insights into the life sciences industry.

Investor Fireside Chat

This exclusive webinar will delve into the growing interest among investors in early-stage funding and explore their motivations, investment strategies, and insights drawn from years in the industry. Attendees will gain valuable perspectives on how investors evaluate life science startups and understand which trends and innovations are catching their attention.

Whether you’re an emerging biotech entrepreneur, a founder exploring funding options, or an industry professional curious about the evolving investment landscape, this webinar will provide actionable insights and strategies to help you navigate the complex world of early-stage funding.

RESI-London-2024-1100px

RESI-JPM-2025-1100PX

Hot Investor Profile: Global Life Sciences Provider Invests and Partners With Technology-Enabled Platform Companies 

A global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients has broad expertise in development sciences, delivery technologies, and multi-modality manufacturing. The firm is a preferred partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The firm has launched a joint venture investment fund to invest strategically in early-stage startups and platforms. By investing in new technologies, partnering with innovators through co-development and in-licensing, across the academic and industry, the firm helps to bring disruptive innovation to the market. The firm invests globally but has primarily partnered with companies in North America and Europe to date. 
 
The firm invests in technology-enabled platform life sciences companies that are relevant to its science and technology and corporate innovation initiatives. Illustrative potential investments include next-generation biomanufacturing platforms, drug delivery platforms, drug-device combinations, cell-line engineering, mAb discovery, development tools, and inputs. The firm will consider investing in companies advancing therapeutic assets if they are also developing platforms technologies. 
 
The firm can lead or co-invest, and while it considers a board seat a plus, it is not a requirement after investing. The firm values the experience of serial entrepreneurs when partnering and focuses on strategic and deeper relationships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Pharma Corporate Venture Arm Seeks to Invest in Therapeutics & Platform Technology Companies in the US and Europe

A corporate venture arm of a pharmaceutical based in the US is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. 
 
The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine. 
 
The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company Mitsubishi Tanabe Pharma. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Looks to Invest in Pre-Seed to Series A Companies Working on Digital Health Technologies, Focusing on North America 

A venture capital firm based in the US is seeking to invest in Pre-Seed to Series A companies, with typical check sizes between $100K and $1M. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from outside of North America. 
 
Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies. 
 
The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Formed by Medical Device Experts Seek to Invest in Early-Stage Medtech Companies Interested in China Market Entry

A group founded by medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel,  pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China. 
 
The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses. 
 
The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Single Family Office Actively Involved in Cross-Border Investments Into Healthcare Companies Leveraging Technology

A multi-asset strategy single family office is involved in real estate management and venture investments. The group has offices in US and China, and the firm’s venture investment arm seeks to invest in early-stage, innovative technology companies. The firm typically engages in seed to series A rounds and prefers life science and healthcare companies with high-tech components. The initial check size from $100K-1M USD. The firm is interested in companies based in the US. 

The firm possesses extensive expertise in cross border investments and collaboration. The firm can leverage its local networks and resources if their portfolio companies have the willingness to expand their businesses in China on various fronts, such as securing additional funding. Because of this unique strategic advantage, the firm maintains a special interest in companies with a China angle and firms with products or technologies suited for the Chinese market. 

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment. 
 
The firm seeks life science and healthcare companies that incorporate high-tech components, such as AI in healthcare and life sciences. The firm is open to considering medical devices, and digital health, and its opportunistic regarding subsectors and indications. Due to the scientific background of its team, the firm is particularly interested in chronic diseases such as diabetes and cardiovascular diseases. 
 
There are no specific requirements for the company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.